Company Overview
Company Type: Private Company
Website: www.duchesnay.com
Number of Employees: 100
Year Founded: -
Total Amount Raised (CAD mm)†: -
Total Rounds of Funding**:-
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Duchesnay Inc. develops pharmacological solutions for women during pregnancy and lactation. The company’s products include Diclectin, an antinauseant/antiemetic drug used for the management of Nausea and Vomiting; PregVit, a supplement that allow attaining nutrient levels of folic acid, iron, and calcium; and Proctofoam-HC, a mucoadhesive analgesic and anti-inflammatory foam for the relief of anorectal inflammation and swelling. It also offers LadySystem, a feminine therapy to treat urinary stress incontinence caused by pelvic floor weakening; and Pediatric for the symptomatic treatment of urinary incontinence and/or increased urinary frequency and urgency in pediatric patients. The company is based in Blainville, Canada.


Financial Information (Currency: CAD, in mm)
Total Revenue
 38.6
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
 100
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
No Key Professionals have been profiled.


Primary Industry Classification
Pharmaceuticals


Primary Office Location
950, boul. Michèle-Bohec | Blainville, QC | J7C 5E2 | Canada
Phone: 450-433-7734   Fax: 450-433-2211


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
LadySystem
As of May 6, 2010, LadySystem was acquired by Duchesnay Inc. LadySystem manufactures female specific therapeutic components such as cones. Duchesnay Inc. is based in Blainville, Canada.

United States and Canada
Health Care Equipment
-
-
-
Duchesnay Usa, Inc.

United States and Canada
-
4.00
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
May-6-2010
May-6-2010
Merger/Acquisition
Buyer
LadySystem
Duchesnay Inc.

-
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Jun-21-2022
Product-Related Announcements
Duchesnay Announces the Launch of Vablys® (Dequalinium Chloride Vaginal Tablets), an Antiseptic and Anti-Infective Treatment for Bacterial Vaginosis
May-17-2022
Product-Related Announcements
Duchesnay Inc. Announces Slynd (Drospirenone), A New Progestin-Only Contraceptive Pill from Duchesnay Which Offers 24-Hour Safe Window for A Missed Pill
Feb-14-2022
Product-Related Announcements
Duchesnay Inc. Announces the First Treatment Launch
Jan-26-2021
Business Expansions
Duchesnay Invests $3 Million at its Blainville Plant and Increases its Export Capacity
Nov-30-2020
Client Announcements
Population Council and Duchesnay Announce New International License Agreement for ANNOVERA®

Competitors
Allergan plc, Alvogen, Inc., AMAG Pharmaceuticals, Inc., Amneal Pharmaceuticals, Inc. (NYSE:AMRX), Glenmark Pharmaceuticals, Inc., Novo Nordisk A/S (CPSE:NOVO B), Perrigo Company plc (NYSE:PRGO), Pfizer Inc. (NYSE:PFE), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Teva Pharmaceuticals USA, Inc., TherapeuticsMD, Inc. (NasdaqGS:TXMD), Viatris Inc. (NasdaqGS:VTRS)


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 14, 2023 07:15 PM
Duchesnay Inc.
Duchesnay Inc
Reports
33
GlobalData

Aug 29, 2023 01:52 AM
Duchesnay Inc.
Duchesnay Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
20
GlobalData

Jun 15, 2023 02:12 AM
Duchesnay Inc.
Duchesnay Inc
Reports
33
GlobalData

May 17, 2023 05:33 AM
Duchesnay Inc.
Duchesnay Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
20
GlobalData

Mar 15, 2023 01:36 AM
Duchesnay Inc.
Duchesnay Inc
Reports
33
GlobalData

Feb 10, 2023 05:18 AM
Duchesnay Inc.
Duchesnay Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
20
GlobalData

Dec 27, 2022 03:04 AM
Duchesnay Inc.
Duchesnay Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
20
GlobalData

Dec 14, 2022 02:33 AM
Duchesnay Inc.
Duchesnay Inc
Reports
34
GlobalData

Sep 16, 2022 07:07 AM
Duchesnay Inc.
Duchesnay Inc
Reports
34
GlobalData

Sep 15, 2022 09:00 AM
Duchesnay Inc.
Duchesnay Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
20


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
Diclectin (Future), Osphena (Future), Pregvit, Pregvit Folic 5, Prevegyne


Upcoming Events
Date/Time
Type
Oct-24-2023
Conferences
Oct-24-2023 9:00 AM (EDT)
Company Conference Presentations
* Future Events are subject to change.

Key Executives and Professionals Details
No Key Executives and Professionals exist.

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
